Weaver Consulting Group Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Weaver Consulting Group cut its position in shares of Pfizer Inc. (NYSE:PFE) by 19.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,675 shares of the biopharmaceutical company’s stock after selling 2,638 shares during the period. Weaver Consulting Group’s holdings in Pfizer were worth $283,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Sterneck Capital Management LLC raised its position in shares of Pfizer by 76.2% in the fourth quarter. Sterneck Capital Management LLC now owns 32,630 shares of the biopharmaceutical company’s stock worth $866,000 after acquiring an additional 14,107 shares during the period. Range Financial Group LLC acquired a new position in Pfizer in the 4th quarter worth about $353,000. Oliver Luxxe Assets LLC boosted its position in Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 401 shares in the last quarter. Neville Rodie & Shaw Inc. grew its holdings in Pfizer by 8.7% in the fourth quarter. Neville Rodie & Shaw Inc. now owns 104,728 shares of the biopharmaceutical company’s stock valued at $2,779,000 after purchasing an additional 8,365 shares during the period. Finally, Pensionfund Sabic increased its position in shares of Pfizer by 41.7% in the fourth quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company’s stock valued at $2,255,000 after buying an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Stock Up 0.9 %

Shares of PFE opened at $27.12 on Wednesday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $26.27 and a two-hundred day simple moving average of $28.07. The company has a market capitalization of $153.69 billion, a PE ratio of 36.65, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the firm earned ($0.17) earnings per share. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.34%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 232.43%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Guggenheim decreased their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $32.15.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.